Get the Stockscreener App
1.85
1.60%
-0.03
After Hours:
1.92
0.07
+3.78%
Immuron Limited Adr stock is traded at $1.85, with a volume of 4,222.
It is down -1.60% in the last 24 hours and down -4.15% over the past month.
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.
See More
Previous Close:
$1.88
Open:
$1.8557
24h Volume:
4,222
Relative Volume:
0.16
Market Cap:
$10.03M
Revenue:
$2.35M
Net Income/Loss:
$-2.56M
P/E Ratio:
-4.1285
EPS:
-0.4481
Net Cash Flow:
-
1W Performance:
+0.54%
1M Performance:
-4.15%
6M Performance:
-2.63%
1Y Performance:
-25.93%
1-Day Range:
$1.8402
$1.875
1-Week Range:
$1.75
$1.94
52-Week Range:
$1.50
$2.87
Immuron Limited Adr Stock (IMRN) Company Profile
Compare IMRN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMRN
Immuron Limited Adr
|
1.85 | 10.03M | 2.35M | -2.56M | 0 | -0.4481 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.30 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
521.00 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.83 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.14 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
241.20 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Immuron Limited Adr Stock (IMRN) Latest News
immuron ltd files for quotation of securities on ASX By Investing.com - Investing.com South Africa
immuron ltd files for quotation of securities on ASX - Investing.com
Immuron Letter to Shareholders: Projects Update - GlobeNewswire Inc.
Immuron and Calmino join up to treat Irritable Bowel Syndrome (IBS) - Markets Insider
Immuron: Targeted oral antibodies to treat infectious diseases - Innovation News Network
NMRC Reports Results for Campylobacter Controlled Human Infection Model Study - GlobeNewswire
Immuron: US FDA provides favourable feedback ahead of investigational new drug application for IMM-529 - Proactive financial news
Immuron requests pre-IND meeting for IMM-529 with FDA filing - GlobeNewswire
Why PriceSmart Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket - Markets Insider
U.S. shares higher at close of trade; Dow Jones Industrial Average up 0.34% - Investing.com UK
Immuron Limited Announces Participation in the LD Micro Invitational XIII - The Kingston Whig-Standard
Immuron Surges On U.S. DoD Funding For Travelan Research By Investing.com - Investing.com Nigeria
Immuron US DoD Naval Medical Research Center Receives feedback on IND Application for New Campylobacter ETEC Therapeutic - StockTitan
Immuron LimitedADR Shares Close the Week 61.5% HigherWeekly Wrap - Nasdaq
IMRNImmuron Ltd Latest Stock News & Market Updates - Stock Titan
Immuron Limited Trade Ideas — NASDAQ:IMRN - TradingView
IMC Reports Rising Revenues & Eyes Colitis Market - Next Investors
IMC Stock Price and Chart — ASX:IMC - TradingView
Immuron Limited Adr Stock (IMRN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
1.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):